Exonate announces the formation of ophthalmology Clinical Advisory Board (“Exonate” or the “Company”)

Ophthalmology leaders to support early stage biotechnology company with potential to revolutionise current standard-of-care in the treatment of eye diseases   Cambridge, UK – 8 November: Exonate, an early stage biotechnology company, today announces the formation of its Clinical Advisory Board (CAB) to support the scientific, pre-clinical development of a revolutionary eye-drop treatment for retinal…

Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)

Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need   Cambridge, UK. Monday 6th February 2017 – Exonate, an early stage biotechnology company has been awarded a £4.9m Seeding Drug Discovery award by the Wellcome Trust to continue development of an eye – drop treatment for wet age–related macular degeneration.  …

Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD)

Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD) New and existing investors participated in the round Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need Cambridge, UK. Wednesday [30th] November 2016 – Exonate, an early stage biotechnology company, today announced they…

Exonate closes second successful funding round

Early stage biotechnology company targeting ophthalmology and potentially pain and cancer Funding to develop treatment for wet age-related macular degeneration (wet AMD) Cambridge, UK, Monday 5th October 2015 – Exonate, an early stage biotechnology company, today announced they have successfully closed their latest funding round including investment from the Angel CoFund. This brings the total…